BioSpace News Archive

According to Latest Report Study, the global alcoholic hepatitis therapeutics market size was valued at US$ 0.7 billion in 2021 and is expected to reach US$ 1.3 billion by 2030 expanding at a CAGR of 6% from 2022 to 2030.

Sequana Medical NV announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies London Healthcare Conference, taking place from 15 to 17 November 2022.

Jiangsu Recbio Technology Co., Ltd. is pleased to announce that positive results were achieved for its primary vaccination Phase II study in the Philippines and heterologous booster vaccination Phase II study in United Arab Emirates in respect of its recombinant COVID-19 vaccine ReCOV.

Roivant Sciences Ltd. announced the pricing of its primary and secondary public offering of 30,000,000 common shares of Roivant, consisting of 20,000,000 common shares offered by Roivant and 10,000,000 common shares offered by the selling shareholders at a price to the public of $5.00 per share for total gross proceeds of $150 million, consisting of total gross proceeds to Roivant of approximately $100 million and total gross proceeds to the selling shareholders of approximately $50 million.

Mallinckrodt plc (NYSE American: MNK) (“Mallinckrodt” or the “Company”), a global specialty pharmaceutical company, today reported results for the third quarter ended September 30, 2022.1

Asensus Surgical, Inc. today announced that the Dr. von Hauner Children’s Hospital at the Ludwig Maximilians University Munich (“LMU”), has entered into an agreement to lease and utilize a Senhance® Surgical System.

Orchard Therapeutics, a global gene therapy leader, announced that members of the management team will present at the following investor conferences.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the Guggenheim 4th Annual Immunology and Neurology Conference 2022 on Monday, November 14, 2022, at 11:20 AM ET, to be held at the St. Regis Hotel in New York, NY.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today reported financial results and provided a business update for the third quarter ended September 30, 2022.

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported third quarter 2022 financial and operating results.